Europe Insomnia Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The EMEA Insomnia Market is expected to reach $ 1,905 million by 2024. This is expected to be the same size by 2032. This stability, combined with a CAGR of 3.3% from 2023 to 2032, suggests a stable demand for insomnia-related products and services. This is a result of an increasing awareness of sleep disorders and an increased focus on mental health, which has pushed consumers to seek effective solutions to insomnia. The market is also supported by technological advances in sleep technology, the rise of telehealth services and a greater focus on individualized medicine. Wearables and sleep-related mobile applications are increasingly popular and enable consumers to monitor and manage their sleep health. Several market leaders, such as Pfizer, Merck and J&J, are investing heavily in research and development and forming strategic alliances to launch new insomnia-related products. These initiatives not only increase the scope of their products, but also meet the changing needs of consumers looking for effective and accessible insomnia treatments.

Regional Market Size

Regional Deep Dive

The EMEA Insomnia Market is characterized by an increasing awareness of sleep disorders and a growing demand for effective treatments. The market is influenced by factors such as increasing stress, changing lifestyles and the growing importance of mental health. In addition, the region is seeing a strong rise in new therapies, such as digital health solutions and natural remedies, which are changing the face of insomnia treatment. Regulatory developments are also taking place in this market, and some governments are aiming to improve access to sleep disorder treatments, which in turn will boost market growth.

Europe

• CBT-I is becoming more and more common as a treatment for insomnia, with the European Sleep Research Society supporting the use of evidence-based practices.
• The European Medicines Agency (EMA) has recently updated guidelines for the approval of sleep aids, emphasizing the need for comprehensive safety data, which is expected to influence the development of new insomnia medications.

Asia Pacific

• The Asia-Pacific region is witnessing a rise in the adoption of traditional medicine approaches, such as Ayurveda and acupuncture, for insomnia treatment, reflecting cultural preferences for holistic health solutions.
• Key players like Takeda Pharmaceutical are investing in research to develop region-specific insomnia treatments that cater to the unique lifestyle and dietary habits prevalent in various Asian countries.

Latin America

• In Latin America, the market is seeing a rise in the popularity of sleep tracking technologies, with companies like Sleep Number introducing smart beds that monitor sleep patterns and provide personalized recommendations.
• Government health programs in countries like Brazil are beginning to include sleep health as part of their public health initiatives, aiming to address the rising prevalence of insomnia among the population.

North America

• The North American insomnia market is experiencing a significant shift towards telehealth services, with companies like Talkspace and BetterHelp expanding their offerings to include sleep therapy, making treatment more accessible.
• Recent regulatory changes by the FDA have led to the approval of new sleep medications, such as lemborexant, which are designed to target specific sleep pathways, providing patients with more tailored treatment options.

Middle East And Africa

• In the Middle East and Africa, there is a growing recognition of sleep disorders as a public health issue, with initiatives from the World Health Organization aimed at raising awareness and improving treatment access.
• Local companies are increasingly focusing on developing natural sleep aids, leveraging indigenous herbs and plants, which resonate well with cultural practices and preferences in the region.

Did You Know?

“Approximately 30% of adults in the EMEA region report experiencing insomnia symptoms, with a significant portion of these individuals not seeking treatment due to stigma or lack of awareness.” — World Health Organization (WHO)

Segmental Market Size

In the EMEA insomnia market, a stable growth is based on increasing public awareness of sleep disorders and a rising prevalence of insomnia across all age groups. The main drivers of the market are the growing concern for mental health and well-being, and the government support for sleep health initiatives. Also, technological advancements in sleep tracking and treatment options have increased the consumers’ engagement and access to solutions. In this context, the market is currently in a mature stage of development, with notable players like Philips and ResMed leading the way in the development of sleep solutions. The main solutions are sleep trackers, CBT-I and sleep medications. Moreover, pandemics like COVID-19 have triggered a surge in the number of insomnia cases, which have prompted further investments in sleep health technology. Also, the integration of artificial intelligence into sleep trackers is shaping the market’s evolution, as the users are able to receive more individualized insights and treatment recommendations.

Future Outlook

The EMEA insomnia market is forecast to grow at a CAGR of 3.3% from 2024 to 2032. This growth is expected to be driven by the rising prevalence of insomnia and sleep disorders, which are gaining more public health importance. As more individuals seek treatment for their sleep disorders, the penetration rate of insomnia therapies in the region is expected to rise. In 2032, it is estimated that around 15-20% of the EMEA adult population will be actively seeking treatment for insomnia, compared with the current estimate of 10-15%. Also, a number of key technological developments, particularly in digital health solutions such as sleep-tracking applications and telemedicine, are expected to transform the landscape for insomnia management. These innovations not only increase patient engagement, but also facilitate a more individualized approach to treatment and make it easier for patients to access care. In addition, supportive government initiatives to improve mental health services and reduce barriers to accessing treatment are expected to further boost the market. In addition, the integration of CBT-I into standard care and the growing acceptance of complementary and alternative therapies will also have a significant impact on the market.